Specific keynote: experimental models of epithelial ovarian carcinogenesis

Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.

International journal of cancer·2014

The stem-cell profile of ovarian surface epithelium is reproduced in the oviductal fimbriae, with increased stem-cell marker density in distal parts of the fimbriae.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2013

Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis?

Gynecologic oncology·2013

The origin of ovarian cancers--hypotheses and controversies.

Frontiers in bioscience (Scholar edition)·2013

TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells.

PloS one·2012

EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells?

PloS one·2012

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Gynecologic oncology·2026

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.

Gynecologic oncology·2026

Evaluating a patient ambassador program to improve clinical trial knowledge and intent to discuss gynecologic oncology trials.

Gynecologic oncology·2026

Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old).

Gynecologic oncology·2026

Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?

Gynecologic oncology·2026

Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.

Gynecologic oncology·2026

Targeting Ferroptosis and Cuproptosis in Ulcerative Colitis: Findings from Comprehensive Bioinformatics and Experimental Validation.

Journal of visualized experiments : JoVE·2026

Field cancerization in urothelial carcinoma: molecular alterations and clinical implications.

Journal of Cancer·2026

Cotinine Promotes Cancer Cell Proliferation and m1A RNA Methylation in Smoking-Associated Lung Cancer by Targeting PLK1/β-Catenin/TRMT6 Axis.

Environment & health (Washington, D.C.)·2026

The role of the neuro-immune-bone axis in osteoporosis: from bone remodeling imbalance to multi-system interactions.

Frontiers in immunology·2026

PKM2 is the Metabolic Checkpoint for Stemness Features in Head and Neck Cancer.

Journal of Cancer·2026

Integrin β1 signaling at the crossroads of cellular plasticity, the tumor microenvironment, and therapy resistance in medulloblastoma.

Frontiers in oncology·2026

Related Experiment Videos

Specific keynote: experimental models of epithelial ovarian carcinogenesis

Related Concept Videos

Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.

The stem-cell profile of ovarian surface epithelium is reproduced in the oviductal fimbriae, with increased stem-cell marker density in distal parts of the fimbriae.

Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis?

The origin of ovarian cancers--hypotheses and controversies.

TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells.

EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells?

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.

Evaluating a patient ambassador program to improve clinical trial knowledge and intent to discuss gynecologic oncology trials.

Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old).

Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?

Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.

Targeting Ferroptosis and Cuproptosis in Ulcerative Colitis: Findings from Comprehensive Bioinformatics and Experimental Validation.

Field cancerization in urothelial carcinoma: molecular alterations and clinical implications.

Cotinine Promotes Cancer Cell Proliferation and m1A RNA Methylation in Smoking-Associated Lung Cancer by Targeting PLK1/β-Catenin/TRMT6 Axis.

The role of the neuro-immune-bone axis in osteoporosis: from bone remodeling imbalance to multi-system interactions.

PKM2 is the Metabolic Checkpoint for Stemness Features in Head and Neck Cancer.

Integrin β1 signaling at the crossroads of cellular plasticity, the tumor microenvironment, and therapy resistance in medulloblastoma.

Related Experiment Videos

Specific keynote: experimental models of epithelial ovarian carcinogenesis

Related Concept Videos

Related Articles